INTRODUCTION
COVID-19 has been associated with venous and arterial thromboembolic disease likely due to potent local and systemic cytokine production with subsequent platelet activation, thrombin stimulation, and fibrin deposition [1]. Such thromboembolic disease is treated with anticoagulation but there are no guidelines to direct the types and duration of oral anticoagulation. We present a case of COVID-associated acute coronary syndrome (ACS) and left ventricular thrombi with resolution of the thrombi within 2 months of warfarin initiation.